{"url_path":"/sec/inmb/8-k/2026-06-02/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 Other Events.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-02","source_url":"https://www.sec.gov/Archives/edgar/data/1711754/0001213900-26-064144-index.html","accession_number":"0001213900-26-064144","cik":"0001711754","ticker":"INMB","issuer_name":"Inmune Bio, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1711754/0001213900-26-064144-index.html","primary_entity_key":"0001711754","primary_entity_name":"Inmune Bio, Inc."},"word_count":75,"has_tables":true,"body_markdown":"**Item 8.01. Other Events.**\n\n \n\nOn June 2, 2026, INmune\nBio Inc. issued a press release announcing results from exploratory chi-separation (χ-separation) MRI imaging analyses from the MINDFuL\nPhase 2 clinical trial of XPro™ (XPro1595) in patients with early Alzheimer's disease encompassing both mild cognitive impairment\n(MCI) and mild Alzheimer’s disease dementia.\n\n \n\nA copy of the press release is attached as Exhibit\n99.1 to this Current Report on Form 8-K and is incorporated herein by reference."}